Current and new strategies in immunotherapy for superficial bladder cancer

Urology

Volumn 64, Issue 3, 2004, Pages 409-421

  Perabo, Frank G E ^a,b   Müller, Stefan C ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b PO Box 1906 ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BROPIRIMINE; EPIRUBICIN; ETOGLUCID; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN; PSEUDOMONAS EXOTOXIN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RUBRATIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN;

ANOREXIA; BLADDER CANCER; BLADDER SPASM; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATURIA; HUMAN; LEUKOPENIA; MYALGIA; NAUSEA; NEUTROPENIA; ORCHITIS; PAIN; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROSTATITIS; REVIEW; SIDE EFFECT; TOXICITY; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY FREQUENCY; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIAL VACCINES; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOSINE; EXOTOXINS; HEART DISEASES; HEMOCYANIN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKINS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 4444323756     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.04.026     Document Type: Review

References (49)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. Cancer J Clin. 49:1999;8-31
2. Epstein J.I., Amin M.B., Reuter V.R., et al. for the Bladder Consensus Conference Committee The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 22:1998;1435-1448
3. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1992;573-580
4. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer an analysis of 315 cases. J Urol. 127:1982;250-252
5. Orozco R.E., Martin A.A., Murphy W.M. Carcinoma in situ of the urinary bladder clues to host involvement in human carcinogenesis. Cancer. 74:1994;115-122
6. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer progression and recurrence. J Urol. 130:1983;1083-1086
7. Stavropoulos N.E., Hastazeris K., Filiadis I., et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer - results of a controlled prospective study. Scand J Urol Nephrol. 36:2002;218-222
8. Rajala P., Kaasinen E., Raitanen M., et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence a prospective randomized multicenter study - FinnBladder III long-term results. J Urol. 168:2002;981-985
9. Mohanty N.K., Malhotra V., Nayak R.L., et al. Combined low-dose intravesical immunotherapy (BCG+interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder a five-year follow-up. J Chemother. 14:2002;194-197
10. Malmstrom P.U. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int. 89:2002;681-686
11. O'Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. J Urol. 166:2001;1300-1304
12. Bazarbashi S., Raja M.A., El Sayed A., et al. Prospective phase II trial of alternating intravesical bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder preliminary results. J Surg Oncol. 74:2000;181-184
13. Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer a prospective randomized multicenter study - Finnbladder III. J Urol. 161:1999;1133-1135
14. Giannakopoulos S., Gekas A., Alivizatos G., et al. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol. 82:1998;829-834
15. Jimenez-Cruz J.F., Vera-Donoso C.D., Leiva O., et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1) multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology. 50:1997;529-535
16. Portillo J., Martin B., Hernandez R., et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology. 4:1997;187-190
17. Stricker P., Pryor K., Nicholson T., et al. Bacillus Calmette- Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology. 48:1996;957-961
18. Raitanen M.P., Lukkarinen O. the Finnish Multicentre Study Group. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Br J Urol. 76:1995;697-701
19. da Silva F.C., Furtado L., Reis M., et al. for the Portuguese Genito-Urinary Group Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors. Eur Urol. 28:1995;291-296
20. Kalble T., Beer M., Mendoza E., et al. BCG vs interferon A for prevention of recurrence of superficial bladder cancer a prospective randomized study. Urol A. 33:1994;133-137
21. Boccardo F., Cannata D., Rubagotti A., et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b results of a multicentric Italian study. J Clin Oncol. 12:1994;7-13
22. Engelmann U., Knopf H.J., Graff J. the Project Group Bochum - Interferon and Superficial Bladder Cancer. Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer - a prospective, controlled three-armed trial. Anticancer Drugs. 3:(suppl 1):1992;33-37
23. Bartoletti R., Massimini G., Criscuolo D., et al. Interferon alfa 2a in superficial bladder cancer prophylaxis toleration and long-term follow-up - a phase I-II study. Anticancer Res. 11:1991;2167-2170
24. Hoeltl W., Hasun R., Albrecht W., et al. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Br J Urol. 68:1991;495-498
25. Glashan R.W. A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol. 144:1990;658-661
26. Chodak G.W. Intravesical interferon treatment of superficial bladder cancer. Urology. 34:(suppl):1989;84-86
27. Torti F.M., Shortliffe L.D., Williams R.D., et al. Alpha-interferon in superficial bladder cancer a Northern California Oncology Group study. J Clin Oncol. 6:1988;476-483
28. Ackermann D., Biedermann C., Bailly G., et al. Treatment of superficial bladder tumors with intravesical recombinant interferon alpha-2a. Urol Int. 43:1988;85-88
29. Den Otter W., Dobrowolski Z., Bugajski A., et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma regression of marker lesion in 8 of 10 patients. J Urol. 159:1998;1183-1186
30. Ferlazzo G., Magno C., Iemmo R., et al. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2 a follow-up study. Anticancer Res. 16:1996;979-980
31. Tubaro A., Stoppacciaro A., Velotti F., et al. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol. 28:1995;297-303
32. Gomella L.G., McGinnis D.E., Lattime E.C., et al. Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2 a pilot study. Cancer Biother. 8:1993;223-227
33. Weiss G.R., O'Donnell M.A., Loughlin K., et al. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother. 26:2003;343-348
34. Glazier D.B., Bahnson R.R., McLeod D.G., et al. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer an Eastern Cooperative Oncology Group study. J Urol. 154:1995;66-68
35. Serretta V., Piazza B., Pavone C., et al. Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors? A phase II study. Int J Urol. 2:1995;100-103
36. Serretta V., Corselli G., Piazza B., et al. Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha preliminary report of a phase I-II study. Eur Urol. 22:1992;112-114
37. Sternberg C.N., Arena M.G., Pansadoro V., et al. Recombinant tumor necrosis factor for superficial bladder tumors. Ann Oncol. 3:1992;741-745
38. Jurincic-Winkler C.D., Metz K.A., Beuth J., et al. Keyhole limpet hemocyanin for carcinoma in situ of the bladder a long-term follow-up study. Eur Urol. 37:(suppl 3):2000;45-49
39. Jurincic C.D., Engelmann U., Gasch J., et al. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin a randomized study. J Urol. 139:1988;723-726
40. Lamm D.L., Dehaven J.I., Riggs D.R. Keyhole limpet hemocyanin immunotherapy of bladder cancer laboratory and clinical studies. Eur Urol. 37:(suppl 3):2000;41-42
41. Flamm J., Donner G., Bucher A., et al. Topical immunotherapy (KLH) vs. chemotherapy (ethoglucid) in prevention of recurrence of superficial bladder cancer a prospective randomized study. Urol A. 33:1994;138-143
42. Kalble T., Mohring K., Ikinger U., et al. Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH a prospective randomized study. Urol A. 30:1991;118-121
43. Akaza H., Shimazaki J., Tashiro K., et al. for the Bropirimine Study Group Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Gan To Kagaku Ryoho. 26:1999;2049-2053
44. Witjes W.P., Konig M., Boeminghaus F.P., et al. for the European Bropirimine Study Group Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. Eur Urol. 36:1999;576-581
45. De Reijke T.M., de Boer E.C., Schamhart D.H., et al. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy - a phase I/II study. Urol Res. 25:1997;117-120
46. Goldberg M.R., Heimbrook D.C., Russo P., et al. Phase I clinical study of the recombinant oncotoxin TP-40 in superficial bladder cancer. Clin Cancer Res. 1:1995;57-59
47. Mengs U., Schwarz T., Bulitta M., et al. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res. 20:2000;3565-3568
48. Elsasser-Beile U., Ruhnau T., Freudenberg N., et al. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer. 91:2001;998-1004
49. Smith J.A., Labasky R.F., Cockett A.T., et al. Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol. 162:1999;1697-1701